AI assistant
GYRE THERAPEUTICS, INC. — Director's Dealing 2018
Feb 22, 2018
32556_dirs_2018-02-22_6442f03d-ef13-4649-b496-f2cd6ed4b1d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST BIOSCIENCES, INC. (CBIO)
CIK: 0001124105
Period of Report: 2018-02-20
Reporting Person: DESOUZA ERROL B (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-02-20 | Redeemable Convertible Note | $137.85 | J | Disposed | Common Stock (78) | Direct | ||
| 2018-02-20 | Redeemable Convertible Note | $137.85 | J | 4679 | Disposed | Common Stock (33) | Direct |
Footnotes
F1: Reflects a 1:15 reverse stock split effected on February 10, 2017.
F2: Reflects a redeemable convertible note of the Issuer (the "Note") that matured, with the face value of the Note repaid to the Reporting Person.
F3: At the option of the Reporting Person, at any time on or before February 19, 2018, the Note was redeemable into cash at a rate of $1 for each $1 principal amount of the Note or convertible into shares of common stock of the Issuer at a conversion rate of $137.85 per share, respectively.
F4: The Note matured on February 19, 2018.